PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.26
D/E ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.16. Howard Marks would check for debt covenant compliance and refinancing risks.
-0.81
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 1.88. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
0.69
Coverage of 0.69 versus zero Drug Manufacturers - Specialty & Generic median interest expense. Walter Schloss would verify if our leverage provides advantages.
5.19
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.39. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
40.44%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.87%. Michael Burry would check for aggressive accounting and hidden risks.